comparemela.com

Latest Breaking News On - James mike wells - Page 1 : comparemela.com

ResBiotic Raises $3M in Seed Funding

Resbiotic, Inc., a Bilmingham, Ala.-based biotech startup, raised $3M in seed funding. The round was funded from a private equity syndicate led by Timberline Holdings. Braxton Goodrich (Timberline Holdings) will serve on the ResBiotic Board of Directors. The company intends to use the funds for the development and commercialization of probiotic formulations for lung health. ResBiotic is the flagship company of ResBiotech Innovation Institute, founded by physician scientist Dr. C Vivek Lal in 2020. ResBiotic’s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal’s Pulmonary Microbiome Lab at UAB with research and expertise from the university’s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development (TReNDD) program. The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company’s research and development

ResBiotic, Inc Raises $3M Seed Round and Announces Leadership Team

Share this article Share this article BIRMINGHAM, Ala., April 29, 2021 /PRNewswire/ University of Alabama at Birmingham s biotech startup Resbiotic, Inc. today announced a $3M seed round to support the development and commercialization of groundbreaking probiotic formulations for lung health. The round was funded from a private equity syndicate led by Timberline Holdings.   ResBiotic is the flagship company of ResBiotech Innovation Institute, founded by physician scientist Dr. C Vivek Lal in 2020. ResBiotic s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal s Pulmonary Microbiome Lab at UAB with research and expertise from the university s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development (TReNDD) program. The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company s research and development pipeline a

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.